Anti-osteoporosis effects of 1,4-dihydroxy-2-naphthoic acid in ovariectomized mice with increasing of bone density

Kenichiro Kita, Eiki Yamachika, Masakazu Matsubara, Hidetsugu Tsujigiwa, Nobuhisa Ishida, Norifumi Moritani, Tatsushi Matsumura, Masahide Mizutani, Yuki Fujita, Kiyofumi Takabatake, Kenichiro Ejima, Hitoshi Nagatsuka, Yoshinori Yamaguchi, Seiji Iida

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: 1,4-Dihydroxy-2-naphthoic acid (DHNA) is the main component of the metabolic products after fermentation by Propionibacterium freudenreichii ET-3. In this study, DHNA, vitamin K2 (VK2), and risedronate (Ris) were administered to ovariectomized (OVX) mice to ascertain their suppressive effects on bone mass reduction. Methods: Fifty mice were divided into five groups: Sham, OVX, DHNA, VK2, and Ris groups. The drugs were administered daily for 8 weeks. Subsequently, blood was collected from the orbital venous plexus. The bilateral femurs and L5 lumbar vertebra were excised. To determine the effects of the drugs, we performed histomorphometric analyses of the left femur and L5 by micro-CT, biochemical analyses of serum samples, and histological analyses of the right femur. Results: The results for the total bone mineral density, bone volume density, trabecular thickness, trabecular number, trabecular separation, and histological analyses showed that bone resorption was improved in the DHNA and Ris groups compared with the OVX group. Furthermore, the biochemical analyses revealed that the production of inflammatory cytokines was suppressed in the DHNA and Ris groups. Conclusions: The present findings show that DHNA suppresses the bone mass reduction in OVX mice, suggesting that it could be an alternative treatment for postmenopausal osteoporosis.

Original languageEnglish
Pages (from-to)66-72
Number of pages7
JournalJournal of Oral and Maxillofacial Surgery, Medicine, and Pathology
Volume28
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Bone Density
Osteoporosis
Femur
Vitamin K 2
Bone and Bones
Lumbar Vertebrae
Postmenopausal Osteoporosis
Bone Resorption
Pharmaceutical Preparations
Fermentation
1,4-dihydroxy-2-naphthoic acid
2-naphthoic acid
Cytokines
Risedronate Sodium
Serum

Keywords

  • Bone resorption
  • DHNA
  • Osteoporosis
  • Ovariectomized mice
  • Risedronate

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Pathology and Forensic Medicine
  • Surgery
  • Oral Surgery

Cite this

@article{9367adc98a97423bbfe620eecac6ee2c,
title = "Anti-osteoporosis effects of 1,4-dihydroxy-2-naphthoic acid in ovariectomized mice with increasing of bone density",
abstract = "Objective: 1,4-Dihydroxy-2-naphthoic acid (DHNA) is the main component of the metabolic products after fermentation by Propionibacterium freudenreichii ET-3. In this study, DHNA, vitamin K2 (VK2), and risedronate (Ris) were administered to ovariectomized (OVX) mice to ascertain their suppressive effects on bone mass reduction. Methods: Fifty mice were divided into five groups: Sham, OVX, DHNA, VK2, and Ris groups. The drugs were administered daily for 8 weeks. Subsequently, blood was collected from the orbital venous plexus. The bilateral femurs and L5 lumbar vertebra were excised. To determine the effects of the drugs, we performed histomorphometric analyses of the left femur and L5 by micro-CT, biochemical analyses of serum samples, and histological analyses of the right femur. Results: The results for the total bone mineral density, bone volume density, trabecular thickness, trabecular number, trabecular separation, and histological analyses showed that bone resorption was improved in the DHNA and Ris groups compared with the OVX group. Furthermore, the biochemical analyses revealed that the production of inflammatory cytokines was suppressed in the DHNA and Ris groups. Conclusions: The present findings show that DHNA suppresses the bone mass reduction in OVX mice, suggesting that it could be an alternative treatment for postmenopausal osteoporosis.",
keywords = "Bone resorption, DHNA, Osteoporosis, Ovariectomized mice, Risedronate",
author = "Kenichiro Kita and Eiki Yamachika and Masakazu Matsubara and Hidetsugu Tsujigiwa and Nobuhisa Ishida and Norifumi Moritani and Tatsushi Matsumura and Masahide Mizutani and Yuki Fujita and Kiyofumi Takabatake and Kenichiro Ejima and Hitoshi Nagatsuka and Yoshinori Yamaguchi and Seiji Iida",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.ajoms.2015.07.001",
language = "English",
volume = "28",
pages = "66--72",
journal = "Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology",
issn = "2212-5558",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Anti-osteoporosis effects of 1,4-dihydroxy-2-naphthoic acid in ovariectomized mice with increasing of bone density

AU - Kita, Kenichiro

AU - Yamachika, Eiki

AU - Matsubara, Masakazu

AU - Tsujigiwa, Hidetsugu

AU - Ishida, Nobuhisa

AU - Moritani, Norifumi

AU - Matsumura, Tatsushi

AU - Mizutani, Masahide

AU - Fujita, Yuki

AU - Takabatake, Kiyofumi

AU - Ejima, Kenichiro

AU - Nagatsuka, Hitoshi

AU - Yamaguchi, Yoshinori

AU - Iida, Seiji

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objective: 1,4-Dihydroxy-2-naphthoic acid (DHNA) is the main component of the metabolic products after fermentation by Propionibacterium freudenreichii ET-3. In this study, DHNA, vitamin K2 (VK2), and risedronate (Ris) were administered to ovariectomized (OVX) mice to ascertain their suppressive effects on bone mass reduction. Methods: Fifty mice were divided into five groups: Sham, OVX, DHNA, VK2, and Ris groups. The drugs were administered daily for 8 weeks. Subsequently, blood was collected from the orbital venous plexus. The bilateral femurs and L5 lumbar vertebra were excised. To determine the effects of the drugs, we performed histomorphometric analyses of the left femur and L5 by micro-CT, biochemical analyses of serum samples, and histological analyses of the right femur. Results: The results for the total bone mineral density, bone volume density, trabecular thickness, trabecular number, trabecular separation, and histological analyses showed that bone resorption was improved in the DHNA and Ris groups compared with the OVX group. Furthermore, the biochemical analyses revealed that the production of inflammatory cytokines was suppressed in the DHNA and Ris groups. Conclusions: The present findings show that DHNA suppresses the bone mass reduction in OVX mice, suggesting that it could be an alternative treatment for postmenopausal osteoporosis.

AB - Objective: 1,4-Dihydroxy-2-naphthoic acid (DHNA) is the main component of the metabolic products after fermentation by Propionibacterium freudenreichii ET-3. In this study, DHNA, vitamin K2 (VK2), and risedronate (Ris) were administered to ovariectomized (OVX) mice to ascertain their suppressive effects on bone mass reduction. Methods: Fifty mice were divided into five groups: Sham, OVX, DHNA, VK2, and Ris groups. The drugs were administered daily for 8 weeks. Subsequently, blood was collected from the orbital venous plexus. The bilateral femurs and L5 lumbar vertebra were excised. To determine the effects of the drugs, we performed histomorphometric analyses of the left femur and L5 by micro-CT, biochemical analyses of serum samples, and histological analyses of the right femur. Results: The results for the total bone mineral density, bone volume density, trabecular thickness, trabecular number, trabecular separation, and histological analyses showed that bone resorption was improved in the DHNA and Ris groups compared with the OVX group. Furthermore, the biochemical analyses revealed that the production of inflammatory cytokines was suppressed in the DHNA and Ris groups. Conclusions: The present findings show that DHNA suppresses the bone mass reduction in OVX mice, suggesting that it could be an alternative treatment for postmenopausal osteoporosis.

KW - Bone resorption

KW - DHNA

KW - Osteoporosis

KW - Ovariectomized mice

KW - Risedronate

UR - http://www.scopus.com/inward/record.url?scp=84952863033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952863033&partnerID=8YFLogxK

U2 - 10.1016/j.ajoms.2015.07.001

DO - 10.1016/j.ajoms.2015.07.001

M3 - Article

VL - 28

SP - 66

EP - 72

JO - Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology

JF - Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology

SN - 2212-5558

IS - 1

ER -